Skip to main navigation Skip to search Skip to main content

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

  • John C. Byrd
  • , John M. Pagel
  • , Farrukh T. Awan
  • , Andres Forero
  • , Ian W. Flinn
  • , Delva P. Deauna-Limayo
  • , Stephen E. Spurgeon
  • , Leslie A. Andritsos
  • , Ajay K. Gopal
  • , John P. Leonard
  • , Amy J. Eisenfeld
  • , Jeannette E. Bannink
  • , Scott C. Stromatt
  • , Richard R. Furman
  • Ohio State University
  • Fred Hutchinson Cancer Research Center
  • Georgia Regents University
  • University of Alabama at Birmingham
  • Sarah Cannon Research Institute
  • Nevada Cancer Institute
  • Oregon Health & Science University
  • Cornell University
  • Emergent Product Development Seattle, LLC, Seattle, WA

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume123
Issue number9
DOIs
StatePublished - Feb 27 2014
Externally publishedYes

Disciplines

  • Pharmacology
  • Medicine and Health Sciences
  • Gastroenterology
  • Internal Medicine

Cite this